Differentiation and histogenesis of syringomatous tumour of the nipple and low-grade adenosquamous carcinoma: evidence for a common origin
Corresponding Author
Werner Boecker
Institute for Hematopathology, Reference Centre for Gynaeco- and Breast Pathology, Hamburg, Germany
Gerhard-Domagk-Institute of Pathology, University of Muenster, Münster, Germany
Address for correspondence: W Boecker and I Buchwalow, Reference Centre for Breast and Gynaecopathology, Institute for Haematopathology, Fangdieckstr. 75, 22547 Hamburg, Germany. e-mail: [email protected] and [email protected]Search for more papers by this authorGöran Stenman
Sahlgrenska Cancer Centre, Department of Pathology, University of Gothenburg, Gothenburg, Sweden
Search for more papers by this authorMattias K Andersson
Sahlgrenska Cancer Centre, Department of Pathology, University of Gothenburg, Gothenburg, Sweden
Search for more papers by this authorHans-Peter Sinn
Institute of Pathology, University Clinic, Heidelberg, Germany
Search for more papers by this authorPeter Barth
Gerhard-Domagk-Institute of Pathology, University of Muenster, Münster, Germany
Search for more papers by this authorFelix Oberhellmann
Gerhard-Domagk-Institute of Pathology, University of Muenster, Münster, Germany
Search for more papers by this authorInge Bos
Institute of Pathology, University of Lübeck, Lübeck, Germany
Search for more papers by this authorTobias Berg
Institute for Hematopathology, Reference Centre for Gynaeco- and Breast Pathology, Hamburg, Germany
Search for more papers by this authorZlatko Marusic
Department of Pathology, Clinical Hospital Centre Sestre Milosrdnice, Zagreb, Croatia
Search for more papers by this authorVera Samoilova
Institute for Hematopathology, Reference Centre for Gynaeco- and Breast Pathology, Hamburg, Germany
Search for more papers by this authorCorresponding Author
Igor Buchwalow
Institute for Hematopathology, Reference Centre for Gynaeco- and Breast Pathology, Hamburg, Germany
Address for correspondence: W Boecker and I Buchwalow, Reference Centre for Breast and Gynaecopathology, Institute for Haematopathology, Fangdieckstr. 75, 22547 Hamburg, Germany. e-mail: [email protected] and [email protected]Search for more papers by this authorCorresponding Author
Werner Boecker
Institute for Hematopathology, Reference Centre for Gynaeco- and Breast Pathology, Hamburg, Germany
Gerhard-Domagk-Institute of Pathology, University of Muenster, Münster, Germany
Address for correspondence: W Boecker and I Buchwalow, Reference Centre for Breast and Gynaecopathology, Institute for Haematopathology, Fangdieckstr. 75, 22547 Hamburg, Germany. e-mail: [email protected] and [email protected]Search for more papers by this authorGöran Stenman
Sahlgrenska Cancer Centre, Department of Pathology, University of Gothenburg, Gothenburg, Sweden
Search for more papers by this authorMattias K Andersson
Sahlgrenska Cancer Centre, Department of Pathology, University of Gothenburg, Gothenburg, Sweden
Search for more papers by this authorHans-Peter Sinn
Institute of Pathology, University Clinic, Heidelberg, Germany
Search for more papers by this authorPeter Barth
Gerhard-Domagk-Institute of Pathology, University of Muenster, Münster, Germany
Search for more papers by this authorFelix Oberhellmann
Gerhard-Domagk-Institute of Pathology, University of Muenster, Münster, Germany
Search for more papers by this authorInge Bos
Institute of Pathology, University of Lübeck, Lübeck, Germany
Search for more papers by this authorTobias Berg
Institute for Hematopathology, Reference Centre for Gynaeco- and Breast Pathology, Hamburg, Germany
Search for more papers by this authorZlatko Marusic
Department of Pathology, Clinical Hospital Centre Sestre Milosrdnice, Zagreb, Croatia
Search for more papers by this authorVera Samoilova
Institute for Hematopathology, Reference Centre for Gynaeco- and Breast Pathology, Hamburg, Germany
Search for more papers by this authorCorresponding Author
Igor Buchwalow
Institute for Hematopathology, Reference Centre for Gynaeco- and Breast Pathology, Hamburg, Germany
Address for correspondence: W Boecker and I Buchwalow, Reference Centre for Breast and Gynaecopathology, Institute for Haematopathology, Fangdieckstr. 75, 22547 Hamburg, Germany. e-mail: [email protected] and [email protected]Search for more papers by this authorAbstract
Aims
Syringomatous tumour of the nipple and low-grade adenosquamous carcinoma (LGAdSC) of the breast are regarded as distinct entities. To clarify the nature of these two lesions, we compared the expression of different lineage/differentiation markers in 12 syringomatous tumours of the nipple, nine LGAdSCs, and normal breast epithelium.
Methods and results
Using triple immunofluorescence labelling and quantitative RT-PCR for keratins, p63, and smooth muscle actin, we demonstrated that syringomatous tumour and LGAdSC contain p63+/K5/14+ tumour cells, K10+ squamous cells, and K8/18+ glandular cells, with intermediary cells being found in both lineages. Identical p63+/K5/14+ cells were also found in the normal breast duct epithelium.
Conclusions
Our data provide evidence that syringomatous tumour of the nipple and LGAdSC are identical or nearly identical lesions. They contain p63+/K5/14+ cells as the key cells from which the K10+ squamous lineage and the K8/18+ glandular lineage arise. On the basis of our findings in normal breast tissue and associated benign lesions, we suggest that p63+/K5/14+ cells of the normal breast duct epithelium or early related cells might play a key role in the neoplastic transformation of both syringomatous tumour and LGAdSC. We propose that the differentiation patterns found in both lesions reflect the early ontogenetic stages of the normal breast epithelium.
Supporting Information
| Filename | Description |
|---|---|
| his12358-sup-0001-FigS1.JPGimage/jpg, 255.6 KB | Figure S1. Syringoma of the nipple. |
| his12358-sup-0002-FigS2.JPGimage/jpg, 169.5 KB | Figure S2. Syringoma of the nipple. |
| his12358-sup-0003-FigS3.JPGimage/jpg, 520.6 KB | Figure S3. Mixed adenomatous and syringomatous adenoma of the nipple. |
| his12358-sup-0004-FigS4.jpgimage/jpg, 326.3 KB | Figure S4. Low-grade adenosquamous carcinoma with transformation to squamous carcinoma. |
| his12358-sup-0005_TableS1.docWord document, 46.5 KB | Table S1. Syringoma of the nipple. |
| his12358-sup-0006_TableS2.docWord document, 43.5 KB | Table S2. Low-grade adenosquamous carcinoma. |
| his12358-sup-0007-Legends.docWord document, 31 KB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Carter E, Dyess DL. Infiltrating syringomatous adenoma of the nipple: a case report and 20-year retrospective review. Breast J. 2004; 10; 443–447.
- 2Rosen PP, Ernsberger D. Low-grade adenosquamous carcinoma. A variant of metaplastic mammary carcinoma. Am. J. Surg. Pathol. 1987; 11; 351–358.
- 3Suster S, Moran CA, Hurt MA. Syringomatous squamous tumors of the breast. Cancer 1991; 67; 2350–2355.
10.1002/1097-0142(19910501)67:9<2350::AID-CNCR2820670923>3.0.CO;2-D PubMed Web of Science® Google Scholar
- 4Eusebi V, Lester S. Syringomatous tumour. In SR Lakhani, IO Ellis, SJ Schnitt, PH Tan, MJ Vijver eds. World Health Organization classification of tumours of the breast. Lyon: IARC Press, 2012; 151.
- 5Jones MW, Norris HJ, Snyder RC. Infiltrating syringomatous adenoma of the nipple. A clinical and pathological study of 11 cases. Am. J. Surg. Pathol. 1989; 13; 197–201.
- 6Van Hoeven KH, Drudis T, Cranor ML, Erlandson RA, Rosen PP. Low-grade adenosquamous carcinoma of the breast. A clinocopathologic study of 32 cases with ultrastructural analysis. Am. J. Surg. Pathol. 1993; 17; 248–258.
- 7Denley H, Pinder SE, Tan PH et al. Metaplastic carcinoma of the breast arising within complex sclerosing lesion: a report of five cases. Histopathology 2000; 36; 203–209.
- 8Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. World Health Organization classification of tumors of the breast. Lyon: IARC Press, 2012.
- 9Geyer FC, Lambros MB, Natrajan R et al. Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod. Pathol. 2010; 23; 951–960.
- 10Gobbi H, Simpson JF, Jensen RA, Olson SJ, Page DL. Metaplastic spindle cell breast tumors arising within papillomas, complex sclerosing lesions, and nipple adenomas. Mod. Pathol. 2003; 16; 893–901.
- 11Reis-Filho JS, Lakhani SR, Gobbi H, Sneige N. Low-grade adenosquamous carcinoma. In SR Lakhani, IO Ellis, SJ Schnitt, PH Tan, MJ Vijver eds. World Health Organization classification of tumours of the breast. Lyon: IARC Press, 2012; 48.
- 12Boecker W, Junkers T, Reusch M et al. Origin and differentiation of breast nipple syringoma. Sci. Rep. 2012; 2; 226. (Available online Sci. Rep. 2, 226; DOI: 10.1038/srep00226 (2012))
- 13Ku J, Bennett RD, Chong KD, Bennett IC. Syringomatous adenoma of the nipple. Breast 2004; 13; 412–415.
- 14Chang CK, Jacobs IA, Calilao G, Salti GI. Metastatic infiltrating syringomatous adenoma of the breast. Arch. Pathol. Lab. Med. 2003; 127; e155–e156.
- 15Foschini MP, Eusebi V. Carcinomas of the breast showing myoepithelial cell differentiation. A review of the literature. Virchows Arch. 1998; 432; 303–310.
- 16Foschini MP, Krausz T. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including ‘triple negative carcinomas’ of low malignant potential. Semin. Diagn. Pathol. 2010; 27; 77–90.
- 17Foschini MP, Pizzicannella G, Peterse JL, Eusebi V. Adenomyoepithelioma of the breast associated with low-grade adenosquamous and sarcomatoid carcinomas. Virchows Arch. 1995; 427; 243–250.
- 18Slaughter MS, Pomerantz RA, Murad T, Hines JR. Infiltrating syringomatous adenoma of the nipple. Surgery 1992; 111; 711–713.
- 19Buchwalow IB, Boecker W. Immunohistochemistry: basics and methods. 1st ed. Heidelberg, Dordrecht, London, New York: Springer, 2010.
10.1007/978-3-642-04609-4 Google Scholar
- 20Buchwalow IB, Minin EA, Boecker W. A multicolor fluorescence immunostaining technique for simultaneous antigen targeting. Acta Histochem. 2005; 107; 143–148.
- 21Boecker W, Stenman G, Loening T et al. K5/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiation. Mod. Pathol. 2013; 26; 1086–1100.
- 22Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell. Biochem. 1998; 31; 205–262.
- 23Brown JK, Pemberton AD, Wright SH, Miller HR. Primary antibody-Fab fragment complexes: a flexible alternative to traditional direct and indirect immunolabeling techniques. J. Histochem. Cytochem. 2004; 52; 1219–1230.
- 24Hui AB, Shi W, Boutros PC et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab. Invest. 2009; 89; 597–606.
- 25Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403–410.
- 26Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000; 37; 232–240.
- 27Bhargava R, Beriwal S, McManus K, Dabbs DJ. CK5 is more sensitive than CK5/6 in identifying the ‘basal-like’ phenotype of breast carcinoma. Am. J. Clin. Pathol. 2008; 130; 724–730.
- 28Delgallo WD, Rodrigues JR, Bueno SP, Viero RM, Soares CT. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma. Cytopathology 2010; 21; 259–266.
- 29Kornegoor R, Verschuur-Maes AH, Buerger H, van Diest PJ. The 3-layered ductal epithelium in gynecomastia. Am. J. Surg. Pathol. 2012; 36; 762–768.
- 30Boecker W, Moll R, Poremba C et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab. Invest. 2002; 82; 737–746.
- 31Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem. Cell Biol. 2008; 129; 705–733.
- 32Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31; 11–24.
- 33Mastropasqua MG, Maiorano E, Pruneri G et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod. Pathol. 2005; 18; 1277–1282.
- 34Senoo M, Pinto F, Crum CP, McKeon F. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007; 129; 523–536.
- 35Signoretti S, Waltregny D, Dilks J et al. p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 2000; 157; 1769–1775.
- 36Nylander K, Vojtesek B, Nenutil R et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J. Pathol. 2002; 198; 417–427.
- 37Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples. Cancer 2003; 99; 172–179.
- 38Reis-Filho JS, Schmitt FC. p63 expression in sarcomatoid/metaplastic carcinomas of the breast. Histopathology 2003; 42; 94–95.
- 39Barbareschi M, Pecciarini L, Cangi MG et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am. J. Surg. Pathol. 2001; 25; 1054–1060.
- 40Batistatou A, Stefanou D, Arkoumani E, Agnantis NJ. The usefulness of p63 as a marker of breast myoepithelial cells. In Vivo 2003; 17; 573–576.
- 41Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J. Invest. Dermatol. 1999; 113; 1099–1105.
- 42Pavlakis K, Zoubouli C, Liakakos T et al. Myoepithelial cell cocktail (p63 + SMA) for the evaluation of sclerosing breast lesions. Breast 2006; 15; 705–712.
- 43Reis-Filho JS, Milanezi F, Paredes J et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl. Immunohistochem. Mol. Morphol. 2003; 11; 1–8.
- 44Xu Z, Wang W, Deng CX, Man YG. Aberrant p63 and WT-1 expression in myoepithelial cells of pregnancy-associated breast cancer: implications for tumor aggressiveness and invasiveness. Int. J. Biol. Sci. 2009; 5; 82–96.
- 45Tseng SC, Jarvinen MJ, Nelson WG, Huang JW, Woodcock-Mitchell J, Sun TT. Correlation of specific keratins with different types of epithelial differentiation: monoclonal antibody studies. Cell 1982; 30; 361–372.
- 46Stoler A, Kopan R, Duvic M, Fuchs E. Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J. Cell Biol. 1988; 107; 427–446.
- 47Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003; 443; 122–132.
- 48Kumar PA, Hu Y, Yamamoto Y et al. Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell 2011; 147; 525–538.
- 49Agrawal A, Saha S, Ellis IO, Bello AM. Adenosquamous carcinoma of breast in a 19 years old woman: a case report. World J. Surg. Oncol. 2010; 8; 44–46.
- 50Laakso M, Tanner M, Nilsson J et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin. Cancer Res. 2006; 12; 4185–4191.
- 51Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9; R4; 1–11.
- 52Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma: a phenotypically distinct entity. Arch. Pathol. Lab. Med. 2010; 134; 130–133.
- 53Jumppanen M, Gruvberger-Saal S, Kauraniemi P et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007; 9; R16. (Available at: http://breast-cancer-research.com/content/9/1/R16).
- 54Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. Basal carcinoma of the breast revisited: an old entity with new interpretations. J. Clin. Pathol. 2008; 61; 553–560.
- 55Lavasani MA, Moinfar F. Molecular classification of breast carcinomas with particular emphasis on ‘basal-like’ carcinoma: a critical review. J. Biophotonics 2012; 5; 345–366.
- 56Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006; 19; 264–271.
- 57Natrajan R, Weigelt B, Mackay A et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res. Treat. 2010; 121; 575–589.
- 58Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367–5374.
- 59Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007; 50; 434–438.
- 60Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res. Treat. 2009; 117; 273–280.
- 61Gusterson B. Do ‘basal-like’ breast cancers really exist? Nat. Rev. Cancer 2009; 9; 128–134.
- 62Lacroix-Triki M, Geyer FC, Weigelt B, Reis-Filho JS. Triple-negative and basal-like carcinoma. Philadelphia, PA: Elsevier Saunders, 2012.
10.1016/B978-1-4377-0604-8.00024-2 Google Scholar
- 63Rosen PP. Rosen's breast pathology. Philadelphia, PA: Lippincott, Williams & Wilkins, 2001; 111–114.
Citing Literature
